Mavyret (Glecaprevir and Pibrentasvir)
Brand Names: Mavyret
Methodology & AI Transparency ⓘ
Mavyret (Glecaprevir and Pibrentasvir) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Formulated with active pharmaceutical ingredient Glecaprevir and Pibrentasvir and registered by AbbVie Inc., Mavyret operates as a prescription brand-name hepatitis c virus ns3/4a protease inhibitor therapy (RxNorm RXN-B00742625; NDC 0074-2625, 0074-2600).
- 2 Real-world patient consensus: Commercial Mavyret monograph (40 mg/1 / 100 mg/1 Tablet, Film Coated) cross-indexed with generic Glecaprevir and Pibrentasvir for therapeutic equivalence review.
- 3 Typical cash cost range: 30-day cash pricing ranges from $640.00 discount cash to $1696.00 walk-in retail (NADAC $152.8336/unit).
- 4 Top reported side effects / signs: Most commonly reported Mavyret (Glecaprevir and Pibrentasvir) tolerability events: nausea (9%), headache (8.4%), dizziness (6.8%).
Ask our AI Specialists anything about Mavyret (Glecaprevir and Pibrentasvir)
Mavyret (Glecaprevir and Pibrentasvir) Mechanism, CYP450 Pathways & DailyMed Monograph
Formulated with active pharmaceutical ingredient Glecaprevir and Pibrentasvir and registered by AbbVie Inc., Mavyret operates as a prescription brand-name hepatitis c virus ns3/4a protease inhibitor therapy (RxNorm RXN-B00742625; NDC 0074-2625, 0074-2600). Under 2026-07-01 FDA labeling for 40 mg/1 / 100 mg/1 Tablet, Film Coated; 20 mg/1 / 50 mg/1 Pellet, FDA-labeled hepatitis c virus ns3/4a protease inhibitor clinical management protocols.
Bioactive Glecaprevir and Pibrentasvir within Mavyret governs hepatitis c virus ns3/4a protease inhibitor target modulation with class-characteristic hepatorenal disposition. Commercialized across 40 mg/1 / 100 mg/1 Tablet, Film Coated; 20 mg/1 / 50 mg/1 Pellet (registered by AbbVie Inc., SPL 2026-07-01), Mavyret combines branded dosage-form consistency (NDC 0074-2625, 0074-2600) with transparent cash-pay comparisons spanning $640.00 to $1696.00.
Systemic exposure to Mavyret (Glecaprevir and Pibrentasvir) reflects Approximately 65% to 77% enteral uptake across labeled Mavyret (Glecaprevir and Pibrentasvir) strengths absorption kinetics and predominantly hepatic biotransformation with renal elimination of polar mavyret (glecaprevir and pibrentasvir) conjugates, sustaining receptor engagement across a Steady-state plasma equilibrium reached over 3–15 hour t½ intervals for Mavyret (Glecaprevir and Pibrentasvir) half-life window (maximum serum exposure occurs 2–4 hours after mavyret (glecaprevir and pibrentasvir) dosing response profile).
Dosing protocols (40 mg/1 / 100 mg/1 Tablet, Film Coated or 20 mg/1 / 50 mg/1 Pellet) balance efficacy (80.00% patient satisfaction across 20 logs) against nausea (9% of reports), headache (8.4% of reports), dizziness (6.8% of reports), with strict avoidance in previous anaphylactoid or exfoliative reaction attributed to mavyret (glecaprevir and pibrentasvir); clinical scenarios where hepatitis c virus ns3/4a protease inhibitor exposure from mavyret (glecaprevir and pibrentasvir) poses unacceptable risk.
Verify medication reconciliation lists so Mavyret (Glecaprevir and Pibrentasvir) is not inadvertently duplicated with another hepatitis c virus ns3/4a protease inhibitor.
Alcohol or high-fat meal timing can shift absorption rate and orthostatic tolerance during Mavyret (Glecaprevir and Pibrentasvir) dosing.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Previous anaphylactoid or exfoliative reaction attributed to Mavyret (Glecaprevir and Pibrentasvir)
- Clinical scenarios where hepatitis c virus ns3/4a protease inhibitor exposure from Mavyret (Glecaprevir and Pibrentasvir) poses unacceptable risk
Logged Side-Effect Incidence (20 Reports)
Mavyret (Glecaprevir and Pibrentasvir) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Mavyret (Glecaprevir and Pibrentasvir))
Human clinical trial evidence for Mavyret (Glecaprevir and Pibrentasvir) is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Mavyret (Glecaprevir and Pibrentasvir) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $152.8336/unit (~$4585.01/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $1696.00 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 20 Anonymous DotMD Community Micro-Logs | $640.00 / mo | View logs ↓ |
Mavyret (Glecaprevir and Pibrentasvir) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Mavyret (Glecaprevir and Pibrentasvir) RxNorm Concept ID | RXN-B00742625 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $152.8336 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $1696.00 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $640.00 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 80.00% Worth It (20 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Mavyret (Glecaprevir and Pibrentasvir) Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Mavyret (Glecaprevir and Pibrentasvir) integrating DailyMed SPL (2026-07-01), CMS NADAC ($152.8336/unit), and 20 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Mavyret (Glecaprevir and Pibrentasvir) community threads and patient logs by age, biological sex, dosage, and treatment duration.